Popular Articles From: First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution and Special Distribution, both in the amount of $0.1625 Per Share to Evolva Sells EV-035 Series to Emergent BioSolutions


2014/12/22
First Trust Intermediate Duration Preferred & Income Fund (the “Fund”) (NYSE: FPF) has declared the Fund’s regularly scheduled monthly common share distribution and special distribution, both in the amount of $0.1625 per share payable on January 15, 2015, to shareholders of record as of December 31, 2014.
Sign-up for First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution and Special Distribution, both in the amount of $0.1625 Per Share investment picks
2015/1/12
First Trust Dividend and Income Fund (the “Fund”) (NYSE: FAV) today declared its regularly scheduled quarterly distribution payable on January 30, 2015, to shareholders of record as of January 26, 2015.
Sign-up for First Trust Dividend and Income Fund Declares Quarterly Distribution of $0.17 Per Share investment picks
2014/12/22
First Trust Advisors L.P. (“FTA”) announces the declaration of distributions for 85 of 94 exchange-traded funds advised by FTA.
Sign-up for First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds investment picks
2015/1/19
First Solar, Inc. (Nasdaq: FSLR) today announced the launch of its Energy Capacity Assessment Tool , a first for the solar energy industry, at the 2015 World Future Energy Summit (WFES). The company will showcase the application and its comprehensive range of solar energy solutions at the Summit in Abu Dhabi, from January 19 to 22, 2015.
Sign-up for First Solar Launches Industry’s First PV Project Assessment Application at WFES 2015 investment picks
2014/12/3
Genzyme , a Sanofi company, today announced that the first U.S. patients have initiated treatment with Lemtrada ® (alemtuzumab) in the commercial setting following its November 14 th FDA approval for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
Sign-up for First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval investment picks
2015/1/29
EDWARDSVILLE, Ill., Jan.
Sign-up for First Clover Leaf Financial Corp. Announces Quarterly Dividend investment picks
2015/1/2
RALEIGH, N.C., Jan.
Sign-up for First Citizens BancShares Completes Merger of Banking Subsidiaries investment picks
2015/1/9
CHAMPAIGN, Ill., Jan.
Sign-up for First Busey Corporation Announces the Acquisition of Herget Financial Corp. and Herget Bank, National Association investment picks
2015/1/15
DIRECTV will host the crown jewel of Super Bowl parties on Saturday, Jan.
Sign-up for Fifth Annual DIRECTV Super Saturday Night to Feature Rihanna investment picks
2014/12/19
Ferro Corporation (NYSE: FOE, “Company”) announced today that it has completed the sale of the majority of the assets of its Polymer Additives business to Polymer Additives, Inc., a wholly owned portfolio company of H.I.G. Capital, LLC, for approximately $154 million in cash, subject to customary working capital and other purchase price adjustments.
Sign-up for Ferro Announces the Sale of Its North America-Based Polymer Additives Business investment picks
2015/1/30
FedEx Corp.
Sign-up for FedEx Completes GENCO Acquisition investment picks
2015/1/13
Netlist Wins Major Legal Victory in Trade Secret, Breach of Contract Lawsuit Against Diablo Technologies, Inc. in Case Involving ULLtraDIMM SSD In Rare Step, Federal Court Orders a Preliminary Injunction Against Diablo Technologies and its Controller Chips Used in Products by SanDisk, IBM, Lenovo, Huawei, and Supermicro OAKLAND, Calif.
Sign-up for Federal Court Orders Halt to Sales of New High-Speed Computer Chips Used by SanDisk, IBM and Other OEMs investment picks
2015/1/26
DexCom, Inc., (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its Dexcom G4 ® PLATINUM Continuous Glucose Monitoring System with Share.
Sign-up for FDA Approves Dexcom G4 Platinum Continuous Glucose Monitoring System with Share investment picks
2014/12/19
By Peter Loftus AbbVie's Viekira Pak, a cocktail of several drugs, cured more than 90% of most common form of hepatitis C U.S. regulators on Friday approved AbbVie Inc.'s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.
Sign-up for FDA approves AbbVie's hepatitis treatment investment picks
2014/12/19
ARCHBOLD, Ohio , Dec.
Sign-up for Farmers & Merchants Bancorp, Inc. Declares 4th Quarter Dividend investment picks
2014/12/31
WASHINGTON , Dec.
Sign-up for Fannie Mae Releases November 2014 Monthly Summary investment picks
2015/1/6
MENLO PARK, Calif.
Sign-up for Facebook to Announce Fourth Quarter and Full Year 2014 Results investment picks
2015/1/21
F5 Networks Inc. (FFIV) shares fell in the extended session Wednesday after the network software company issued a weak outlook for the current quarter.
Sign-up for F5 Networks shares fall on weak outlook investment picks
2015/2/2
Exxon Mobil Corp.
Sign-up for Exxon's 2015 capex plan to be revelead next month investment picks
2015/1/15
http://www.marketwire.com/library/MwGo/2015/1/15/11G030529/Extendicare_Inc.-1387207530938.jpg MARKHAM, ON--(Marketwired - January 15, 2015) - Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) announced today that the Company has entered into a definitive agreement to acquire the Revera Home Health business from Revera Inc. (the "Vendor"), for $83 million in cash, before working capital adjustments (the "Transaction"). The completion of the Transaction is subject to customary closing conditions and regulatory approvals, including assignment of government contracts, and is expected to close following receipt of regulatory approvals.
Sign-up for Extendicare Announces Significant Acquisition to Expand its Canadian Home Health Care Business investment picks
2015/1/15
http://www.marketwire.com/library/MwGo/2015/1/15/11G030509/Extendicare_Inc.-1387207530938.jpg MARKHAM, ON--(Marketwired - January 15, 2015) - Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the "Common Share") for the month of January 2015, which is payable on February 17, 2015 to shareholders of record at the close of business on January 30, 2015.
Sign-up for Extendicare Announces January 2015 Dividend of C$0.04 per Share investment picks
2015/1/12
Exelon today issued the following statement on the State of Illinois report on potential nuclear power plant closings prepared in response to House Resolution 1146: We thank the state for its attention and work on such an important issue for Illinois and the future of the state’s energy assets.
Sign-up for Exelon Statement on Illinois Nuclear Power Plant Report investment picks
2015/2/2
Exelixis, Inc. (NASDAQ: EXEL) announced today that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 24, 2015 after the markets close.
Sign-up for Exelixis to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 24, 2015 investment picks
2015/1/7
Exelixis, Inc. (NASDAQ:EXEL) today announced that it has extended and restructured its agreement with Swedish Orphan Biovitrum AB (Sobi) to support the distribution and commercialization of COMETRIQ ® (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey.
Sign-up for Exelixis and Swedish Orphan Biovitrum AB (Sobi) Extend and Restructure Distribution Agreement for COMETRIQ® for Medullary Thyroid Cancer investment picks
2015/1/8
ROSELAND, NJ --
Sign-up for ExactCare Pharmacy Wins ADP's Beyond the Startup Contest investment picks
2015/1/2
Exact Sciences Corp.
Sign-up for Exact Sciences: Additional Update on CMS Reimbursement for Cologuard® investment picks
2015/1/12
Exact Sciences Corp.
Sign-up for Exact Sciences Offers Update on Cologuard’s® Early Launch Trajectory investment picks
2014/12/18
2K and Turtle Rock Studios announced today that the Open Beta test for the much anticipated 4v1 shooter, Evolve™ , is coming exclusively to Xbox One, the all-in-one games and entertainment system from Microsoft, January 15 – 19, 2015.
Sign-up for Evolve™ Open Beta Exclusively on Xbox One January 15 – 19, 2015 investment picks
2014/12/17
Evolva Holding SA (“Evolva”, SIX:EVE) today announced that Emergent BioSolutions Inc. (“Emergent”, NYSE:EBS) has acquired Evolva’s anti-bacterial programme, the EV-035 series.
Sign-up for Evolva Sells EV-035 Series to Emergent BioSolutions investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Popular Articles From: First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution and Special Distribution, both in the amount of $0.1625 Per Share to Evolva Sells EV-035 Series to Emergent BioSolutions
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent